Crestchem Ltd Board Approves FY26 Results, Dividend & Subsidiary
Crestchem Ltd announced the revised outcome of its board meeting held on May 29, 2026. The board approved the Audited Standalone & Consolidated Financial Results for the quarter and financial year ended March 31, 2026. Additionally, they noted the formation of a subsidiary, Oleo Biosciences Private Limited, incorporated on March 31, 2026, which has not commenced commercial operations. A final dividend of ₹1.50 per equity share (15%) for FY 2025-26 was recommended, subject to shareholder approval. The board also approved the reappointment and remuneration of Mr. Dipak Narendraprasad Patel, Mrs. Parul Dipak Patel, and Mrs. Tansi Nirmit Patel for five-year terms. Investment up to ₹2.25 Crores in the subsidiary was also approved.
Key Highlights
- Approved Audited Standalone & Consolidated Financial Results for FY ended March 31, 2026.
- Recommended a final dividend of ₹1.50 per equity share (15%) for FY 2025-26.
- Noted formation of subsidiary Oleo Biosciences Private Limited.
- Approved reappointment and remuneration for three directors.
- Approved investment up to ₹2.25 Crores in the subsidiary.
Price Impact
More from CRSTCHM